🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New results presented at #ASH24 from the first of our Phase 3 randomized trials for people living with certain blood cancers are promising for those with chronic lymphocytic leukemia or small lymphocytic lymphoma. Learn more: e.lilly/4fqJBi1

New data presented at #SABCS24 demonstrate positive results in people with ER+, HER2- advanced or metastatic breast cancer (MBC). Read more about the potential impact: e.lilly/3D5T9l0

Learn more about a new treatment option for moderate-to-severe obstructive sleep apnea and obesity: e.lilly/402anIX

If you live with a chronic condition such as obesity, psoriasis or psoriatic arthritis, we know how important it is to get the medicines you need. Learn more about steps we’re taking to help. e.lilly/428fl8m #WeAreLilly

Our scientists continue exploring new approaches to breast cancer. Today we announced an agreement to acquire an innovative clinical program from Scorpion Therapeutics. e.lilly/425KFVn

With the annual J.P. Morgan Healthcare Conference underway, we're sharing an update on our 2024 revenue guidance and outlook for 2025. e.lilly/4gPzkNR

News for people living with moderately to severely active #CrohnsDisease: the U.S. FDA has approved a new treatment option for adults living with this chronic inflammatory bowel disease: e.lilly/42h9jTc

Pioneering better medicines means more people get the right medicines. This collaboration with Purdue University and Merck aims to revolutionize how we make medicines—so more people have a chance at better health. #WeAreLilly

In 2024, our medicines gave millions more people a chance at better health. Read more about our Q4 2024 results: e.lilly/4aNxTNr

See long-term response and remission data over two years for patients with moderately to severely active #CrohnsDisease treated with our FDA approved medication. Explore the data presented at #CCCongress25: e.lilly/4jMXiuU

News today: we announced new options to help people living with obesity get authentic Lilly medicine. e.lilly/4gVxREU

We’re dramatically investing to support future breakthroughs in medicine with 4 new U.S. sites. See the details of this latest commitment that more than doubles our domestic manufacturing investment, exceeding $50 billion since 2020: e.lilly/3EYiJJG #WeAreLilly

People facing recurring and unpredictable moderate-to-severe atopic dermatitis (eczema) flares need treatment options that provide long-term, meaningful symptom improvement. Learn more about new data for an approved treatment option presented at #AAD2025: e.lilly/4ilVlEo

An investigational treatment for adolescents living with severe alopecia areata showed improved hair regrowth in the first data reported from a Phase 3 study. Learn more about our late-breaking data presented at #AAD2025: e.lilly/4kAHxre

1 in 5 Americans have a genetic risk factor for heart disease—with no approved medicines. Our scientists are working on a potential new medicine to change that. Results from a mid-stage clinical study were published today in NEJM: e.lilly/4jfmkBV

The FDA confirmed that the shortage of our diabetes and obesity medicines is over, and a federal court rejected compounding pharmacies’ attempt to block the FDA’s decision. e.lilly/3FMMmhk

Lilly has no affiliation with hims & hers. Read our full statement: e.lilly/3QVnEhb

Just in: Positive late-stage trial results for a potential new pill for type 2 diabetes. Read more: e.lilly/4jH5nR3

We’re on our way to helping more people than ever before. For more information, click here: e.lilly/3YlH96D

New today: the full results of a study comparing our obesity medicine to another therapy were published in the NEJM and presented at the European Congress on Obesity. Read more: e.lilly/454tNzC